1. Allen BR A multicentre double blind placebo controlled crossover to assess the efficacy and safety of cyclosporin A in adult patients with severe refractory atopic dermatitis Wolff K Royal Society of Medicine International Congress & Symposium Series Athens, Greece Cyclosporin A and the skin: proceedings, satellite symposium to the 2nd congress of the European Academy of Dermatology & Venereology 1991 29 37
2. Efficacy, safety and pharmacodynamics of a high-affinity anti-IgE antibody in patients with moderate to severe atopic dermatitis: a randomized, double-blind, placebo-controlled, proof-of-concept study;Bangert;Experimental Dermatology,2016
3. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis;Beck;New England Journal of Medicine,2014
4. Systemic treatment of patients with severe atopic dermatitis (AD) with an anti IL-4R alpha mAb (REGN668/SAR231893) results in rapid and sustained improvements in disease signs and symptoms;Beck;Journal of Investigative Dermatology,2013
5. A randomized, double-blind, parallel-group, placebo-controlled study to assess the safety of REGN668 administered concomitantly with topical corticosteroids to patients with moderate-to-severe atopic dermatitis www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000946-37